Mónica Cabrero

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Guillermo Garcia‐Manero, H. Jean Khoury, Elias Jabbour et al. · Clinical Cancer Research · 2014 · 54 citations · Full text

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Talha Badar, Keyur P. Patel, Philip A. Thompson et al. · Leukemia Research · 2015 · 52 citations · Full text

Mutation-based Testing, Engineering, Somatic Variant +9

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

José María Bastida, Mónica Cabrero, Oriana López‐Godino et al. · Leukemia Research · 2015 · 51 citations

Myelodisplastic Syndrome, Hematological Malignancy, Transplantation +12

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

Jorge Labrador, Lucía López‐Corral, Oriana López‐Godino et al. · Bone Marrow Transplantation · 2014 · 51 citations

Thrombopoiesis, Thrombosis, Cell Therapy +14

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

Mónica Cabrero, Elias Jabbour, Farhad Ravandi et al. · Leukemia Research · 2015 · 51 citations · Full text

Hematological Malignancy, Agent Therapy, Medicine +9